OS Therapies Incorporated (OSTX)
NYSE American · Healthcare · Biotechnology
$1.60−1.23%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $74.9M
- Forward P/E
- 4.6
- 52-week range
- $1.15 – $2.25
- 52-week change
- −20.59%
- EPS (trailing)
- −$1.08
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Net income
- −$28.8M
- Diluted EPS
- −$0.98
- Free cash flow
- −$14.7M
From the company’s annual report on SEC EDGAR.
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Headquarters: Grasonville, United States · 4 employees · ostherapies.com